Streetbeat News

Analyst Ratings

LIAN

B of A Securities has downgraded LianBio (NASDAQ:LIAN) from a previous rating to Underperform, with a new price target set at $3.00, down from $5.00. LianBio's shares are currently trading at $4.29, down 1.83% over the last 24 hours. The new price target suggests a potential decrease of 30.07% from the current share price. LianBio is a biopharmaceutical company focusing on developing medicines for unmet medical needs in various therapeutic areas.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:00 pm

PPG

Analysts have mixed views on PPG Industries (NYSE:PPG), with 3 analysts giving ratings ranging from bullish to somewhat bullish over the last three months. The average 12-month price target for PPG is $159.33, with a high of $166.00 and a low of $152.00. The average target has decreased by 1.65%. Citigroup, Keybanc, and Barclays analysts have recently adjusted their price targets and ratings. PPG is a global coatings producer, with strong financial indicators such as a 3.94% revenue growth rate, a net margin of 9.17%, an ROE of 5.55%, an ROA of 1.95%, and a debt-to-equity ratio of 0.9.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:00 pm

OI

Citigroup has downgraded O-I Glass (NYSE:OI) to Neutral, adjusting the price target from $17.00 to $18.00. Despite the downgrade, the new target suggests a potential upside of 16.13% from the current price of $15.50. O-I Glass is a leading manufacturer of glass bottles, with a significant market presence in Europe, North America, and Brazil, and beer as its primary end market.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:00 pm

CHRD

Mizuho analyst Nitin Kumar has maintained a Buy rating on Chord Energy (NASDAQ:CHRD) but has reduced the price target from $197 to $188.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:59 pm

MTDR

Mizuho analyst Nitin Kumar has maintained a Buy rating on Matador Resources (NYSE:MTDR) but has reduced the price target from $83 to $67.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:57 pm

ENOV

William Blair has initiated coverage on Enovis Corp (NYSE:ENOV), an orthopedics-focused medical technology company. The analyst predicts durable share gains and margin expansion for Enovis, with an 8% market penetration expected in 2024. The Outperform rating is based on ENOV shares trading at 11.7 times the firm's pro forma 2024 EBITDA estimate, which is below the average for the orthopedic and medtech growth groups. The valuation accounts for integration risks from the Lima acquisition but is seen as an attractive entry point. Enovis plans to diversify into spine, sports medicine, and trauma, tapping into a $28 billion market segment. Despite trading slightly lower at $55.39, the company's past successful execution supports the potential for long-term growth.

Portfolio Pulse from Vandana Singh

January 03, 2024 | 4:57 pm

SILK

Lake Street analyst Frank Takkinen has initiated coverage on Silk Road Medical (NASDAQ:SILK) with a Buy rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:45 pm

INFY

JP Morgan analyst Ankur Rudra has upgraded Infosys (NYSE:INFY) from Neutral to Overweight, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:42 pm

ZBH

Raymond James analyst Jayson Bedford has maintained an Outperform rating on Zimmer Biomet Holdings (NYSE:ZBH) and increased the price target from $133 to $137.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:40 pm

JNJ

Raymond James analyst Jayson Bedford has maintained an Outperform rating on Johnson & Johnson (NYSE:JNJ) and increased the price target from $172 to $175.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 4:39 pm